ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,522,643, issued on Jan. 13, was assigned to XLIFESC LTD (Guangdong, China).
"High-affinity TCR for AFP recognition" was invented by Yi Li (Guangdong, China) and Liang Chen (Guangdong, China).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided in the present invention is a T-cell receptor (TCR) having the characteristic of binding a FMNKFIYEI-HLA A0201 complex; and the binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 5 times that of a wild-type TCR to the FMNKFIYEI-HLA A0201 complex. Further provided in the present invention is a fusion molecule of the TCR with a therapeutic agent. The TCR can be used alone or in combination ...